Desensitization and Internalization of Mu-Opioid Receptors in the Locus Coeruleus

蓝斑 Mu-阿片受体的脱敏和内化

基本信息

  • 批准号:
    7501240
  • 负责人:
  • 金额:
    $ 4.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-30 至 2009-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Opioids are widely used analgesics; however prolonged use results in tolerance, a progressively decreasing responsiveness to the drug. Desensitization and internalization of u-opioid receptors (MOR) are important in the actions of opioids and appear to contribute to the development of tolerance. Desensitization and internalization have been well characterized in naive cells, but how these processes are regulated in neurons during chronic treatment is unclear. Knowing what cellular adaptations occur in response to chronic agonist exposure will better our understanding of the mechanisms contributing to tolerance. The purpose of this proposal is to investigate how regulation of u-opioid receptor desensitization and endocytosis are altered during chronic morphine treatment. Acute desensitization is an uncoupling of the receptor from G-protein activation that occurs during a sustained application of a high concentration of agonist. Agonist-bound receptors also undergo endocytosis. I hypothesize that an upregulation of agonist-induced internalization occurs in chronic-morphine treated animals, resulting in reduced recovery from desensitization. This hypothesis is based on studies examining alterations in the actions of opioids in rat locus coeruleus neurons following chronic-morphine treatment. Agonist efficacy was decreased, desensitization was facilitated, and recovery was incomplete in LC neurons from chronic-morphine-treated rats. To test my hypothesis, I will record MOR coupling to activation of potassium channels in locus coeruleus (LC) neurons from mice expressing a FLAG-tagged u-opioid receptor (FLAG-MOR). This will allow us to study MOR coupling and trafficking simultaneously in a live brain slice. The first goal of this project is to characterize activation, desensitization, and internalization of FLAG-MOR to [Met]5-enkephalin in naTve cells using a combination of electrophysiology and imaging. The second goal is to treat mice chronically with morphine and determine what role internalization plays in the reduced recovery from desensitization that is observed. Understanding the cellular mechanisms of MOR regulation during chronic exposure to morphine will provide insight into the processes that lead to the development of tolerance to opioids. This understanding may allow for the development of effective analgesics which do not produce tolerance.
描述(由申请人提供):阿片类药物是广泛使用的镇痛剂;然而,长期使用会导致耐受性,对药物的反应性逐渐降低。μ-阿片受体(莫尔)的脱敏和内化在阿片类药物的作用中是重要的,并且似乎有助于耐受性的发展。脱敏和内化已经在幼稚细胞中得到了很好的表征,但是在慢性治疗期间这些过程在神经元中是如何调节的尚不清楚。了解慢性激动剂暴露后发生的细胞适应性变化将有助于我们更好地理解耐受性的机制。本研究的目的是探讨慢性吗啡治疗过程中,阿片受体脱敏和内吞的调节如何改变。急性脱敏是在持续应用高浓度激动剂期间发生的受体与G蛋白活化的解偶联。激动剂结合的受体也经历内吞作用。我推测,激动剂诱导的内化发生在慢性吗啡治疗的动物,导致减少恢复脱敏。这一假设是基于研究慢性吗啡治疗后大鼠蓝斑神经元中阿片类药物作用的改变。激动剂的效力下降,脱敏促进,恢复是不完全的LC神经元从慢性吗啡治疗的大鼠。为了验证我的假设,我将记录莫尔偶联到来自表达FLAG标记的u-阿片受体(FLAG-莫尔)的小鼠的蓝斑(LC)神经元中钾通道的激活。这将使我们能够在活体脑切片中同时研究莫尔偶联和运输。该项目的第一个目标是使用电生理学和成像的组合来表征天然细胞中FLAG-MOR对[Met]5-脑啡肽的激活、脱敏和内化。第二个目标是用吗啡长期治疗小鼠,并确定内化在观察到的脱敏恢复减少中起什么作用。了解慢性吗啡暴露过程中莫尔调节的细胞机制将有助于深入了解阿片类药物耐受性发展的过程。这种理解可能允许开发不产生耐受性的有效镇痛剂。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sex Steroids Do Not Modulate TRPM2-Mediated Injury in Females following Middle Cerebral Artery Occlusion(1,2,3).
  • DOI:
    10.1523/eneuro.0022-14.2014
  • 发表时间:
    2014-11
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Quillinan N;Grewal H;Klawitter J;Herson PS
  • 通讯作者:
    Herson PS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nidia Quillinan其他文献

Nidia Quillinan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nidia Quillinan', 18)}}的其他基金

Developing and characterizing a translational neonatal rat cardiac arrest and cardiopulmonary resuscitation model
开发和表征转化新生大鼠心脏骤停和心肺复苏模型
  • 批准号:
    10591062
  • 财政年份:
    2022
  • 资助金额:
    $ 4.1万
  • 项目类别:
Excitability and plasticity alterations in a novel cerebellar stroke model
新型小脑卒中模型中的兴奋性和可塑性改变
  • 批准号:
    10241346
  • 财政年份:
    2018
  • 资助金额:
    $ 4.1万
  • 项目类别:
Excitability and plasticity alterations in a novel cerebellar stroke model
新型小脑卒中模型中的兴奋性和可塑性改变
  • 批准号:
    10467034
  • 财政年份:
    2018
  • 资助金额:
    $ 4.1万
  • 项目类别:
Differential mechanisms and consequences of Purkinje cell loss in an adult and pediatric model of global cerebral ischemia
成人和儿童全脑缺血模型中浦肯野细胞丢失的不同机制和后果
  • 批准号:
    9096261
  • 财政年份:
    2015
  • 资助金额:
    $ 4.1万
  • 项目类别:
Desensitization and Internalization of Mu-Opioid Receptors in the Locus Coeruleus
蓝斑 Mu-阿片受体的脱敏和内化
  • 批准号:
    7329753
  • 财政年份:
    2007
  • 资助金额:
    $ 4.1万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 4.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了